Overall, these data indicate that EPAS1 is suppressed in obese individuals associated with dyslipidemia and elevated PHD2 and PHD3 expression in EC, an observation that is consistent with our observations in murine models of obesity. Here, EGLN1 is linked to metabolic syndrome.